XASX
TRI
Market cap63mUSD
Nov 02, Last price
0.03AUD
Name
Medibio Ltd
Chart & performance
P/E
—
P/S
103.90
EPS
—
Vol. 1Y
—
Shs. 5Y
94.42%
Rev. 5Y
-35.96%
Div Yld LY
—
Div Yld TTM
—
Revenues
889k
+3,926.59%
Net income
-1m
L-59.71%
CFO
-848k
L-8.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medibio Limited is a health technology firm dedicated to the identification and screening of mental health conditions, serving clients in Australia and the United States. The company provides mental well-being programs for corporations through its corporate health product line and also innovates solutions for the healthcare provider market. Founded in 1987, the enterprise was initially known as BioProspect Limited before rebranding to Medibio Limited in November 2014. Its headquarters are situated in Melbourne, Australia.
Key people
Non-Executive Independent Chairman of the Board · since 2022
Brian Mower
Chief Financial Officer · since 2018
Jeremy Schroetter
Chief Technology Officer
Anthony Keating
Executive Director · since 2024
Archie Defillo
Chief Medical Officer
S. Stapelberg
Marketing Executive · since 2014
Stephen Buckley
Company Secretary · since 2023
Lisa Ide
Non-Executive Director · since 2019
Non-Executive Director · since 2023
Liwanag Ojala
Non-Executive Director · since 2019
Lisa Wipperman Heine
Non-Executive Director · since 2019
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||